Predictive markers useful in the treatment of wet age-related macular degeneration

A method of treating an individual with wet AMD, the method comprising:

• (i) obtaining a sample from an individual having wet AMD;
• (ii) determining the quantity of at least one autoantibody selected from Group A antibodies directed against self antigen selected from the group consisting of opioid growth factor receptor (OGFR), mitogen-activated protein kinase 3 (MAPK3), Poly(rC)binding protein 2 (PolyRp2), Chromosome 17 (open reading frame 56), eukaryotic initiation factor 4A-1 (EIFA 4A-1), glutathione peroxidase 4 (GPX4), signal recognition particle 14 kDa protein (SPR14), Gamma-synuclein, histadine tRNA ligase (Jo-1), Pre-Albumin (transthyretin), glycerol-3-phosphate dehydrogenase (GPD2), AP-1 complex subunit mu-1 (AP1M1), alpha enolase (ENO1-H7), plasticity-related gene 2 (PRG2), ATP synthase, Guanine nucleotide binding protein subunit 1 (GNB 1-A3), tubulin beta-3 chain (TUBB3), heat shock protein 60 (HSP 60), islet cell autoantigen 1 (ICA1), selenoprotein O (SELO}, superoxidase dismutase (SOD), and gamma-enolase (ENO2);
• (iii) identifying the individual as a VEGF antagonist responder if the sample has an amount of the at least one autoantibody selected from Group A antibodies that has increased by at least 10% or decreased by at least 10% compared to a control;
• and
• (iv) administering a VEGF antagonist to the identified individual.